Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 14, Issue 7, 2004, Pages 1645-1649

  Varnes, Jeffrey G ^a   Gardner, Daniel S ^a   Santella III, Joseph B ^a   Duncia, John V ^a   Estrella, Melissa ^a   Watson, Paul S ^a   Clark, Cheryl M ^a   Ko, Soo S ^a   Welch, Patricia ^a   Covington, Maryanne ^a   Stowell, Nicole ^a   Wadman, Eric ^a   Davies, Paul ^a   Solomon, Kimberley ^a   Newton, Robert C ^a   Trainor, George L ^a   Decicco, Carl P ^a   Wacker, Dean A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CHEMOKINE RECEPTOR CCR3; PIPERIDINE DERIVATIVE; SEROTONIN 2A RECEPTOR;

ARTICLE; BINDING AFFINITY; CALCIUM TRANSPORT; CHEMOTAXIS; CHIRALITY; CORRELATION ANALYSIS; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; MOLECULE; STEREOCHEMISTRY;

ANIMALS; CATTLE; CHO CELLS; CRICETINAE; PIPERIDINES; PROTEIN BINDING; RECEPTORS, CHEMOKINE; UREA;

EID: 12144285924     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2004.01.059     Document Type: Article

References (17)

1. Asthma; Barnes, P. J., Grunstein, M. M., Leff, A. R., Woolcock, A. J., Eds.; Vol. 1; Lippincott-Raven Publishers: New York, 1997.
2. Ramshaw H.S., Woodcock J.M., Bagley C.J., McClure B.J., Hercus T.R., Lopez A.F. Immunol. Cell Biol. 79:2001;154.
3. Egan R.W., Umland S.P., Cuss F.M., Chapman R.W. Allergy. 51:1996;71.
4. Kitaura M., Nakajima T., Imai T., Harada S., Combadiere C., Tiffany H.L., Murphy P.M., Yoshie O. J. Biol. Chem. 271:1996;7725.
5. Heath H., Qin S., Rao P., Wu L., LaRosa G., Kassam N., Ponath P.D., Mackay C.R. J. Clin. Invest. 99:1997;178.
6. Hogan S.P., Mishra A., Brandt E.B., Royalty M.P., Pope S.M., Zimmermann N., Foster P.S., Rothenberg M.E. J. Immunol. 2:2001;353.
7. Wacker D.A., Santella J.B. III, Gardner D.S., Varnes J.G., Estrella M., DeLucca G.V., Ko S.S., Tanabe K., Watson P.S., Welch P.K., Covington M., Stowell N.C., Wadman E.A., Davies P., Solomon K.A., Newton R.C., Trainor G.L., Friedman S.M., Decicco C.P., Duncia J.V. Bioorg. Med. Chem. Lett. 12:2002;1785.
8. De Lucca G.V., Kim Ui.T., Johnson C., Vargo B.J., Welch P.K., Covington M., Davies P., Solomon K.A., Newton R.C., Trainor G.L., Decicco C.P., Ko S.S. J. Med. Chem. 45:2002;3794.
9. 5 CHO cells, and 0.0001-1 μM compound in 150 μL of binding buffer (0.5% bovine serum albumen, 10 mM HEPES buffer and 5 mM magnesium chloride in RPMI 1640 media) in 96-well filtration plates (Millipore) pretreated with 5 μg/mL protamine in phosphate buffered saline, pH 7.2. The assay was incubated at room temperature for 30 min. The plates were vacuum filtered and the remaining cells were washed three times with binding buffer containing 0.5 M NaCl added. Radiolabel binding was quantified upon filter removal via liquid scintillation counting.
10. 5 eosinophils preloaded with Fluo-3AM (Molecular Probes) and 0.0001-1 μM compound in 200 μL of buffer (0.1% bovine serum albumen, 20 mM HEPES buffer and 2.5 mM Probenecid in RPMI 1640 media) in 96-well plates in a fluorescent imaging plate reader. Data was generated as arbitrary fluorescence units and compound dependent inhibition was calculated as a percentage of the response of eotaxin alone.
11. Ley S.V., Norman J., Griffith W.P., Marsden S.P. Synthesis. 7:1994;639.
12. Thakur S.K., Hosangadi B.D. Tetrahedron. 52:1996;8755.
13. Brown G.R., Forster G., Foubister A.J., Stribling D.J. Pharm. Pharmacol. 42:1990;797.
14. Hendrix, J.; Strupczewski, J. T.; Bordeau, K. J.; Brooks, S.; Hemmerle, H.; Urmann, M.; Zhao, X.-Y.; Mueller, P. J. World Patent Appl. WO 02066468 A2.
15. Wacker, D.; Duncia, J. V. World Patent Appl. WO 0129000.
16. Thomas E.W. Synthesis. 1993;767.
17. Tanouchi T., Kawamura M., Ohyama I., Kajiwara I., Iguchi Y., Okada T., Taniguchi K., Miyamoto T., Hayashi M. J. Med. Chem. 24:1981;1139.